Holen Sie sich die Stockscreener-App
124.12
0.83%
1.02
Schlusskurs vom Vortag:
$123.10
Offen:
$123.83
24-Stunden-Volumen:
2.12M
Relative Volume:
1.94
Marktkapitalisierung:
$12.46B
Einnahmen:
$2.68B
Nettoeinkommen (Verlust:
$428.00M
KGV:
29.64
EPS:
4.1873
Netto-Cashflow:
$593.10M
1W Leistung:
-12.10%
1M Leistung:
-6.15%
6M Leistung:
-5.70%
1J Leistung:
+6.20%
1-Tages-Spanne:
$123.36
$126.50
1-Wochen-Bereich:
$122.14
$142.82
52-Wochen-Spanne:
$84.23
$160.18
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Firmenname
Neurocrine Biosciences Inc
Sektor
Telefon
(858) 617-7600
Adresse
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
124.12 | 12.35B | 2.68B | 428.00M | 593.10M | 4.1873 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.46 | 58.03B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
126.65 | 55.37B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.20 | 49.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.98 | 39.50B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
473.66 | 20.50B | 3.13B | 1.27B | 1.12B | 26.39 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-21 | Eingeleitet | Citigroup | Buy |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-10 | Eingeleitet | Goldman | Buy |
| 2025-04-15 | Hochstufung | Needham | Hold → Buy |
| 2025-04-14 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-08-29 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | Fortgesetzt | Citigroup | Neutral |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-08-21 | Bestätigt | Mizuho | Neutral |
| 2023-07-24 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-30 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-02-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-09-26 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-06-06 | Fortgesetzt | Jefferies | Buy |
| 2022-03-03 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | Hochstufung | Goldman | Neutral → Buy |
| 2022-01-18 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Underperform |
| 2021-11-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-10-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Fortgesetzt | Needham | Hold |
| 2021-08-06 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | Fortgesetzt | Goldman | Neutral |
| 2021-05-06 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-02-02 | Eingeleitet | Raymond James | Outperform |
| 2020-09-30 | Eingeleitet | The Benchmark Company | Hold |
| 2020-08-04 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-06-29 | Herabstufung | Goldman | Buy → Neutral |
| 2020-06-09 | Eingeleitet | Wedbush | Outperform |
| 2020-03-06 | Eingeleitet | Citigroup | Buy |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-24 | Eingeleitet | William Blair | Outperform |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2020-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-13 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-05 | Eingeleitet | Guggenheim | Neutral |
| 2019-05-21 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-02-06 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-12-13 | Eingeleitet | Goldman | Buy |
| 2018-11-21 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Neurocrine Biosciences Inc Aktie (NBIX) Neueste Nachrichten
Neurocrine Biosciences (NBIX) Is Down 12.1% After Issuing 2026 INGREZZA Sales GuidanceWhat's Changed - simplywall.st
A Look At Neurocrine Biosciences (NBIX) Valuation After Strong 2025 Results And 2026 Guidance - Yahoo Finance
How cyclical is Neurocrine Biosciences Inc.’s revenue streamWeekly Investment Recap & Low Risk Profit Maximizing Plans - mfd.ru
NBIX Rating Maintained, Price Target Lowered by Wells Fargo | NB - GuruFocus
Wells Fargo & Company Issues Pessimistic Forecast for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price - MarketBeat
Krilogy Financial LLC Makes New $1.27 Million Investment in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences Inc (NASDAQ:NBIX) Screens as a Compelling Value Investment - ChartMill
Neurocrine Biosciences Enters New Growth Phase With Broader Revenue Mix - simplywall.st
Neurocrine Biosciences: Growth Beyond Just Ingrezza (NASDAQ:NBIX) - Seeking Alpha
Earnings roundup: Neurocrine slumps, Alnylam battles skeptics and Ascendis eyes a competitor - BioPharma Dive
Neurocrine Biosciences (NASDAQ:NBIX) Given New $204.00 Price Target at Citigroup - MarketBeat
Analysts Stay Bullish As Neurocrine Shares Tumble On Disappointing Ingrezza Guidance - Benzinga
Neurocrine Biosciences: Expanding Opportunities, 2026 Will Be Less Exciting (NASDAQ:NBIX) - Seeking Alpha
Neurocrine Biosciences (NASDAQ:NBIX) Given New $177.00 Price Target at Royal Bank Of Canada - MarketBeat
BMO Capital Markets Has Lowered Expectations for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price - MarketBeat
Neurocrine Biosciences' Ingrezza Remains 'Core Value Driver,' Morgan Stanley Says - marketscreener.com
Wedbush Adjusts Neurocrine Biosciences Price Target to $151 From $149, Maintains Outperform Rating - marketscreener.com
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $151.00 at Wedbush - MarketBeat
Neurocrine Bio. stock price target lowered to $192 at H.C. Wainwright - Investing.com Canada
Neurocrine Biosciences (NASDAQ:NBIX) Stock Price Down 9.3% Following Analyst Downgrade - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) Given New $192.00 Price Target at HC Wainwright - MarketBeat
Needham & Company LLC Lowers Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $185.00 - MarketBeat
RBC Trims Price Target on Neurocrine Biosciences to $177 From $180, Keeps Outperform Rating - marketscreener.com
Neurocrine Biosciences, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2025 Earnings Call Transcript - Insider Monkey
Forecasting The Future: 10 Analyst Projections For Neurocrine Biosciences - Benzinga
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Impax Asset Management Group plc - MarketBeat
Is Neurocrine Biosciences (NBIX) Pricing Reflecting Its Strong 1 Year Share Performance? - simplywall.st
Neurocrine expects INGREZZA sales to reach up to $2.8B in 2026 amid CRENESSITY launch momentum - MSN
Neurocrine Biosciences Q4 2025 Earnings Call Transcript - MarketBeat
Neurocrine (NBIX) Q4 2025 Earnings Call Transcript - The Globe and Mail
Neurocrine Biosciences (NASDAQ:NBIX) Posts Earnings Results, Misses Estimates By $0.48 EPS - MarketBeat
Neurocrine Biosciences Q4 Earnings Call Highlights - MarketBeat
Neurocrine Q4 2025 slides: INGREZZA, CRENESSITY fuel 22% annual growth - Investing.com India
Earnings call transcript: Neurocrine’s Q4 2025 beats forecasts, stock rises By Investing.com - Investing.com India
Earnings call transcript: Neurocrine’s Q4 2025 beats forecasts, stock rises - Investing.com
Neurocrine (NBIX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Neurocrine Biosciences (NBIX) Lags Q4 Earnings Estimates - Yahoo Finance
Neurocrine: Q4 Earnings Snapshot - KVUE
Neurocrine: Fourth Quarter Earnings Overview - Bitget
Neurocrine Biosciences beats Q4 expectations, offers cautious 2026 guidance By Investing.com - Investing.com Australia
Neurocrine Biosciences Fiscal Q4 Adjusted Earnings, Revenue Rise; Sets INGREZZA FY Guidance - marketscreener.com
Neurocrine Biosciences beats Q4 expectations, offers cautious 2026 guidance - Investing.com
Neurocrine Biosciences Inc Profit Advances In Q4 - Nasdaq
Earnings Flash (NBIX) Neurocrine Biosciences, Inc. Reports Q4 Revenue $805.5M, vs. FactSet Est of $790.5M - marketscreener.com
Neurocrine Biosciences (NASDAQ: NBIX) posts 2025 INGREZZA surge and details DOJ probe - Stock Titan
Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026 - PR Newswire
Neurocrine Biosciences Q4 25 Earnings Conference Call At 4:30 PM ET - Nasdaq
Neurocrine earnings in focus as Crenessity launch, Ingrezza rivalry heat up - Investing.com Canada
Wesbanco Bank Inc. Makes New $1.26 Million Investment in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Preview: Neurocrine Biosciences's Earnings - Benzinga
Finanzdaten der Neurocrine Biosciences Inc-Aktie (NBIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.37%
1.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):